Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817072 | 0.81 | MET (0.59) | METAXL | |
| SCHEMBL4817071 | 0.79 | MET (0.47) | METAXL | |
| SCHEMBL4813333 | 0.78 | MAP4K4 (0.42) | METAXLROCK2 | |
| SCHEMBL4817075 | 0.77 | MET (0.65) | MET | |
| SCHEMBL4825650 | 0.71 | MET (0.63) | METAXL | |
| SCHEMBL5928587 | 0.70 | MET (0.64) | MET | |
| SCHEMBL4825643 | 0.69 | MET (0.48) | METAXL | |
| SCHEMBL12406074 | 0.67 | MAP4K4 (0.44) | METAXLJAK1JAK3 | |
| SCHEMBL4821467 | 0.66 | MET (0.56) | METAXLJAK1 | |
| SCHEMBL896074 | 0.64 | MET (0.47) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885AXL 452/4885ROCK2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.